Torregrosa 2007.

Methods	Study design: open‐label, parallel RCT Duration of study: not reported Duration of follow‐up: 12 months
Participants	Country: Spain Setting: Single centre Inclusion criteria: kidney transplant recipients aged 18 to 70 years, SCr < 221 µmol/L; iPTH > 60 pg/mL; BMD T‐score < ‐1 Number: treatment group (39); control group (35) Mean age ± SD (years): treatment group (58 ± 9); control group (55 ± 8) Sex (M/F): treatment group (20/19); control group (22/23) Exclusion criteria: DM
Interventions	Treatment group Risedronate (oral): 35 mg/week Control group No treatment Co‐interventions Calcium carbonate: 2500 mg/d vitamin D3: 800 IU/d
Outcomes	Change in BMD at lumbar spine and femoral neck from months 6 to 12
Notes	Funding source: not reported Trial registration: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	High risk	Unblinded
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Selective reporting (reporting bias)	High risk	Adverse events not reported systematically
Other bias	Low risk	No additional threats to validity identified